Earnings Performance - Worthington Enterprises reported quarterly earnings of $0.74 per share, missing the Zacks Consensus Estimate of $0.80 per share, but showing an increase from $0.50 per share a year ago, resulting in an earnings surprise of -7.50% [1] - The company posted revenues of $303.71 million for the quarter ended August 2025, which was 2.63% below the Zacks Consensus Estimate and an increase from $257.31 million year-over-year [2] Stock Performance - Worthington Enterprises shares have increased approximately 52.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 13.8% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.71 on revenues of $309.4 million, and for the current fiscal year, it is $3.65 on revenues of $1.3 billion [7] - The Zacks Industry Rank indicates that the Building Products - Wood sector is currently in the bottom 7% of over 250 Zacks industries, which may impact the stock's performance [8]

分组1 - MillerKnoll reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.35 per share, and showing an increase from $0.36 per share a year ago, representing an earnings surprise of +28.57% [1] - The company achieved revenues of $955.7 million for the quarter ended August 2025, surpassing the Zacks Consensus Estimate by 4.60%, and an increase from $861.5 million year-over-year [2] - Over the last four quarters, MillerKnoll has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 11.9% since the beginning of the year, while the S&P 500 gained 13.8% [3] - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $970.35 million, and for the current fiscal year, it is $1.81 on revenues of $3.79 billion [7] - The Zacks Industry Rank indicates that the Furniture industry is currently in the bottom 18% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Company Performance - Micron reported quarterly earnings of $3.03 per share, exceeding the Zacks Consensus Estimate of $2.86 per share, and showing a significant increase from $1.18 per share a year ago, representing an earnings surprise of +5.94% [1] - The company achieved revenues of $11.32 billion for the quarter ended August 2025, surpassing the Zacks Consensus Estimate by 0.47%, and up from $7.75 billion year-over-year [2] - Over the last four quarters, Micron has consistently surpassed consensus EPS estimates and topped revenue estimates three times [2] Stock Performance - Micron shares have increased approximately 95.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 13.8% [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating expectations for continued outperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $3.05 on revenues of $12.05 billion, while for the current fiscal year, the estimate is $13.25 on revenues of $50.96 billion [7] - The outlook for the industry, particularly the Computer - Integrated Systems sector, is favorable, ranking in the top 6% of over 250 Zacks industries, which historically outperforms the bottom 50% by more than 2 to 1 [8]

Company Performance - AAR reported quarterly earnings of $1.08 per share, exceeding the Zacks Consensus Estimate of $0.98 per share, and up from $0.85 per share a year ago, representing an earnings surprise of +10.20% [1] - The company posted revenues of $739.6 million for the quarter ended August 2025, surpassing the Zacks Consensus Estimate by 7.86%, compared to $661.7 million in the same quarter last year [2] - AAR has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] Stock Performance - AAR shares have increased approximately 25.5% since the beginning of the year, outperforming the S&P 500's gain of 13.8% [3] - The current consensus EPS estimate for the upcoming quarter is $1.07 on revenues of $706.94 million, and for the current fiscal year, it is $4.43 on revenues of $2.87 billion [7] Industry Outlook - The Aerospace - Defense Equipment industry, to which AAR belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact AAR's stock performance [5]

Key Takeaways NVIDIA and OpenAI recently announced a collaboration. NVIDIA has announced many other deals in 2025 so far. Shares still reflect prime exposure for the AI frenzy. The AI frenzy continues to dominate headlines, with poster-child NVIDIA (NVDA) at the forefront yet again.But why?NVIDIA unveiled a strategic partnership to deploy at least 10 gigawatts of NVIDIA systems for OpenAI’s next-generation AI infrastructure to train and run its next generation of models.And to support the deployment, NVIDIA ...

Company Overview - Xperi (XPER) shares increased by 6.6% to close at $6.51, supported by higher trading volume compared to normal sessions, contrasting with a 1.6% loss over the past four weeks [1] - The company is making progress on key growth initiatives, including enhanced engagement on its TV platform, expansion in connected vehicles, and continued adoption of IPTV [1] Earnings Expectations - Xperi is expected to report quarterly earnings of $0.25 per share, reflecting a year-over-year decline of 51%, with revenues projected at $110.5 million, down 16.9% from the same quarter last year [2] - The consensus EPS estimate for Xperi has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Industry Context - Xperi holds a Zacks Rank of 1 (Strong Buy) within the Technology Services industry, indicating strong market sentiment [4] - Another company in the same industry, NextNav Inc. (NN), saw a 0.6% increase in its stock price, closing at $17.18, with a 9.9% return over the past month [4]

Key Takeaways The White House is drafting executive actions on quantum sciences and post-quantum cryptography.GovCIO reports OSTP's plan highlights commercialization, supply chain security and workforce growth.QBTS, IONQ and RGTI gained sharply this month as federal mandates boost quantum adoption prospects.The Trump administration’s renewed quantum policy push through executive actions and the likely reauthorization of the National Quantum Initiative Act (NQIA) could significantly benefit both pure-play qu ...

Key Takeaways Nasdaq set new intra-day and closing highs, finishing the session at 22,788.98. NVIDIA, Broadcom and ACM Research stood out with high net income ratios.Screening narrowed 7,685 stocks to 74 using profitability and growth metrics.The Nasdaq broke records on Monday, reaching an all-time intraday high. The tech-heavy index also closed the trading session at a record high, finishing at 22,788.98. Hence, it’s judicious for astute investors to keep an eye on companies listed on the Nasdaq that deliv ...

Key Takeaways Finding the top-ranked momentum stocks to buy for October and beyond.Why this soaring, under-the-radar automotive equipment stock is a Zacks Rank #1 (Strong Buy).The stock market is trading at new all-time highs in the final full week of September and the third quarter. The recent surge has been driven by a wave of spending across the artificial intelligence ecosystem as investors, big and small, clamor to make sure they don’t get left behind if there is another huge leg up for Wall Street.Som ...

Key Takeaways Ionis' phase III study showed zilganersen stabilized gait speed in Alexander disease patients.The drug demonstrated favorable safety and consistent benefit across secondary measures.Ionis plans an FDA filing in Q1 2026 as it expands its wholly owned medicine portfolio.Ionis Pharmaceuticals (IONS) announced positive topline results from a pivotal phase III study evaluating its investigational RNA-targeted therapy zilganersen for treating a rare neurological condition called Alexander disease (A ...